P/E ratio for Adicet Bio (ACET)
P/E ratio as of April 2024 (TTM): -0.8088
According to Adicet Bio's latest financial reports and stock price the company's current price-to-earnings ratio (TTM) is -0.808824. At the end of 2022 the company had a P/E ratio of -5.29.
P/E ratio history for Adicet Bio from 2020 to 2023
PE ratio at the end of each year
| Year | P/E ratio | Change |
|---|---|---|
| 2022 | -5.29 | -37.39% |
| 2021 | -8.45 | 138.18% |
| 2020 | -3.55 |
P/E ratio for similar companies or competitors
| Company | P/E ratio | P/E ratio differencediff. | Country |
|---|---|---|---|
 Novartis NVS | 25.2 | -3,220.99% | 🇨🇭 Switzerland |
 Pfizer PFE | 13.9 | -1,822.27% | 🇺🇸 USA |
 Merck MRK | 69.3 | -8,664.43% | 🇺🇸 USA |
 Teva Pharmaceutical Industries TEVA | -6.62 | 717.85% | 🇮🇱 Israel |
 Hawkins HWKN | 23.3 | -2,979.49% | 🇺🇸 USA |
 Quaker Houghton KWR | 409 | -50,622.49% | 🇺🇸 USA |
How to read a P/E ratio?
The Price/Earnings ratio measures the relationship between a company's stock price and its earnings per share. A low but positive P/E ratio stands for a company that is generating high earnings compared to its current valuation and might be undervalued. A company with a high negative (near 0) P/E ratio stands for a company that is generating heavy losses compared to its current valuation.
Companies with a P/E ratio over 30 or a negative one are generaly seen as "growth stocks" meaning that investors typically expect the company to grow or to become profitable in the future.
Companies with a positive P/E ratio bellow 10 are generally seen as "value stocks" meaning that the company is already very profitable and unlikely to strong growth in the future.